Variable | HLA-B15 (n=34) | HLA-B27 (n=70) | Other HLA-B (n=74) | Significant p values |
---|---|---|---|---|
Age±SD—years, mean±SD (n=178) | 35.7±10.0 | 35.8±13.6 | 35.8±13.1 | |
Age of onset—years, mean±SD (n=178) | 28.2±9.4 | 27.7±10.5 | 32.6±10.9 | 0.008* |
Disease duration—years, median (IQR) | 3.4 (2–12) | 3.6 (1–12) | 3.0 (1–11.5) | |
Sex—number of men/women (%) | 15/19 (44/56) | 55/15 (79/21) | 30/44 (40/60) | 0.001† |
Men:women ratio | 0.8:1 | 3.7:1 | 1.46:1 | |
Patients with SpA classified according to ESSG criteria | ||||
Patients having AS (n=91) | 13 | 41 | 37 | |
Patients having uSpA (n=57) | 17 | 15 | 25 | 0.006‡ |
Patients having ReA (n=30) | 4 | 14 | 12 | |
Total (n=178) | 34 | 70 | 74 | |
Patients with SpA classified according to ASAS criteria | ||||
Patients with axSpA manifestations (n=152)§ | 27 | 70 | 55 | <0.0001¶ |
Patients with isolated axSpA (n=12) | 0 | 10 | 2 | 0.050** |
Patients with combined ax/pSpA (n=140) | 27 | 60 | 53 | |
Patients with pSpA manifestations (n=161)†† | 34 | 60 | 67 | 0.050‡‡ |
Patients with isolated pSpA (n=13) | 4 | 0 | 9 | 0.015§§ |
Patients with combined ax/pSpA (n=148) | 30 | 60 | 58 |
Percentages within parenthesis are calculated with respect to the number of patients in each HLA-B group.
Shown significant p values correspond as follows.
*p=0.008, between HLA-B27 and other HLA-B; †p<0.001, both between HLA-B27 and HLA-B15, and between HLA-B27 and other HLA-B alleles; there was no significant difference between HLA-B15 and other HLA-B; ‡p=0.006, between HLA-B15 and HLA-B27; §(n=152), among our 178 patients satisfying the ESSG classification criteria for SpA,2 only 152 met the ASAS criteria for axSpA18 and 26 patients did not; ¶p<0.0001, between HLA-B27 and other HLA-B; **p=0.050, between HLA-B15 and HLA-B27; ††(n=161) indicates that 161 patients (but not the remaining 17 patients) met the ASAS criteria for pSpA.17 ‡‡p=0.050, between HLA-B27 and HLA-B15; §§p=0.015, between HLA-B15 and HLA-B27.
AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis international Society; axSpA, axial spondyloarthritis; ESSG, European Spondyloarthropathy Study Group; HLA, human leucocyte antigen; pSpA, peripheral spondyloarthritis; uSpA, undifferentiated spondyloarthritis; ReA, reactive arthritis; SpA, spondyloarthritis.